Novartis related Press Releases

New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants Data in JAMA show Menveo may provide infants protection against four of the most common Read more...

Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more...

Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Collaboration efforts will focus on the discovery and optimization of antibodies against a significant Read more...

Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies Tasigna produced response in 49% of patients with Read more...

Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more...

New Galvus clinical data reinforces efficacy profile; safety update provided to regulatory agencies New data accepted for publication show Galvus 50 mg twice-daily dose as effective as a Read more...

Novartis International Says U.S. Approves Tasigna Cancer Drug BASEL, SWITZERLAND -- Oct 29, 2007 -- Tasigna® (nilotinib) has been approved in the US as a new anti-cancer therapy for certain Read more...

Novartis Corporation Voltaren Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis PARSIPPANY, N.J., Oct. 22 -- Read more...

Novartis delivers record earnings in first nine months of 2007 thanks to strong operational performance and divestment gains Strong operational performance for Group continuing operations: Read more...

Thompson Scientific Publishes "Who Is Making The Biggest Splash" A QUARTERLY REVIEW OF SCIENTIFIC LITERATURE ON DRUGS AND THERAPIES FROM APRIL – JUNE 2007 Novartis Takes Top Spot, Read more...